Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

COMPLETE IF KNOWN	
Application Number	10/022,939
Filing Date	December 18, 2001
First Named Inventor	R L KENDALL ET AL
Group Art Unit	1646
Examiner Name	C M KAUFMAN
Attorney Docket Number	19963YDB

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
CMK		5,240,848		KECK ET AL	07/10/1989
		5,332,671		FERRARA ET AL	08/04/1989
		5,766,860		TERMAN ET AL	02/25/1997
CMK		5,861,301		TERMAN ET AL	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
CMK			0 506 477 A1		EP	03/27/1992
			WO 92/14748		PCT	09/03/1992
CMK			WO 94/11499		PCT	05/26/1994

Examiner Signature	Clem M. Kaufman	Date Considered	6/11/04

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

COMPLETE IF KNOWN	
Application Number	10/022,939
Filing Date	December 18, 2001
First Named Inventor	R L KENDALL ET AL
Group Art Unit	1646
Examiner Name	C M KAUFMAN
Attorney Docket Number	19963YDB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
CM		Ferrara, N. et al; The Vascular Endothelial Growth Factor Family of Polypeptides; Journal of Cellular Biochemistry, Vol. 47; 1991; pp. 211-218.
		Maglione, D. et al; Two Alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), Are Transcribed from a Single Gene of chromosome 14; Oncogene; Vol 8, 1993, pg. 925-931.
		Hauser, S. et al.; A Heparin-Binding Form of Placenta; Growth Factor (PIGF-2) is Expressed in Human Umbilical Vein Endothelial Cells and in Placenta; Growth Factors; Vol 9, 1993; pp. 259-268.
		Grimmond, S. et al; Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor; Genome Research; Vol 6, 1996; pp. 124-131.
		Olofsson, B. et al; Vascular Endothelial Growth Factor B, A Novel Growth Factor for Endothelial cells; Proc. Natl. Acad Sci. USA, Vol 93, 1996; pp. 2576-2581.
		Joukov, V. et al; A Novel Vascular Endothelial Growth Factor, VEGF-C is a Ligand for the FLT (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases; The EMBO Journal; Vol 15; No. 2; 1996; pp. 290-298.
		Shibuya, M. et al. Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene (FLT) closely Related to the fms Family; Oncogene; Vol. 5, 1990, pp. 519-524.
		Pajusola, K. et al, FLT4 Receptor Tyrosine Kinase Contains Seven Immunogloblin-like Loops and Is Expressed in Multiple Human Tissues and Cell Lines; Cancer Research; Vol. 52, 5738-5743.
		Terman, B.I. et al; Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase; Oncogene; Vol 6, 1991, pp. 1677-1683.
		Terman, B.I. et al; Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor, Biochemical & Biophysical Research Communications; Vol 187, No. 3; 1992, pp. 1579-1586.
CM		Rockwell et al. 'In Vitro Neutralization...Monoclonal Antibody', Mol. Cell Differ., Vol. 3(1), pp. 91-109 (1995).

Examiner Signature	Claire M. Kaufman	Date Considered	6/16/04